Atezolizumab Plus Cobimetinib Improves Cancer Control for Patients with Biliary Tract Cancer
A phase II study presented at AACR found that the combination of atezolizumab plus cobimetinib improved cancer control in some patients with biliary tract cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Possible Predictors of Treatment-Free Remission in Patients with CML
Researchers suggested that treatment-free remission may be successfully obtained with an effector-suppressor score which is calculated using absolute natural killer cells, FoxP3+ regulatory T cells, and monocytic myeloid-derived suppressor cells. (Source: CancerNetwork)
Source: CancerNetwork - May 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Olaparib Maintenance Therapy Improves Survival in Relapsed, BRCA-Positive Ovarian Cancer
Treatment with olaparib in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations. (Source: CancerNetwork)
Source: CancerNetwork - May 13, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Mary-Elizabeth Percival, MD, on Hematologic Malignancies and COVID-19
The oncology hematologist spoke about the guidelines she and her colleagues outlined regarding treating patients with hematologic malignancies during the COVID-19 pandemic. (Source: CancerNetwork)
Source: CancerNetwork - May 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
High Dose CAR T-19 May be More Effective than Low Dose in Patients with CLL
Researchers found that a high dose of CAR T-19 may be more effective than a low dose at inducing a complete response without excessive toxicity. (Source: CancerNetwork)
Source: CancerNetwork - May 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Nivolumab Demonstrates Durable Response in Refractory Biliary Tract Cancer
The phase II study found that nivolumab was well tolerated and demonstrated moderate efficacy with durable response in patients with refractory biliary tract cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Culturally Specific Education Program Improved Knowledge and Screening Rates for CRC
A recent study implemented the Screen to Save program to educate racial/ethnic minority groups on colorectal cancer, finding that knowledge and screenings increased after patients completed the educational program. (Source: CancerNetwork)
Source: CancerNetwork - May 12, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Model Can Predict Patient Outcomes to Immunotherapy, Engineer Proper Regimens
A clinically applicable mathematical model was developed by researchers to predict outcomes to immunotherapy for patients with cancer previously treated with anti –CTLA-4 or anti–PD-1/PD-L1 antibodies. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Racial Inequalities of Liver Cancer Mortality Increase After Introduction of Hepatitis C Drugs
Researchers found a steady increase in racial inequalities of the mortality rate from liver cancer from 1998-2016 after lifesaving drugs for hepatitis C virus were introduced. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma
Researchers found that 2 studied strategies, which combined nivolumab and doxorubicin, vinblastine, and dacarbazine, are feasible, highly effective, and result in excellent 12-month progression-free survival. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Tavo, Pembrolizumab Combo May Aid in Reducing Remissions in Advanced Melanoma
The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates
SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Study Shows Promise for UGN-101 in Low-Grade Upper Tract Urothelial Cancer
The study, titled OLYMPUS, suggested that primary chemoablation of low-grade upper tract urothelial cancer with intracavitary UGN-101 resulted in clinically significant disease eradication. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
PALB2 Germline Mutations Moderately Increased Risk of PALB2-Related Breast Cancer in China
This study analyzed the full prevalence and spectrum of partner and localizer BRCA2 (PALB2) germline mutations in China, focusing on the associations between these PALB2 germline mutations and breast cancer risk. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Improving Time from Diagnosis to Definitive Surgery in Black Patients with Melanoma
Researchers indicated that targeted approaches to improving time from diagnosis to definitive surgery for black patients are essential in reducing racial disparities in melanoma outcomes. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
